Advertisement

Topics

Bayer, Evotec ink research pact for kidney disease

02:22 EDT 23 Sep 2016 | BioPharmaDive

Bayer's second research deal with Evotec could be worth as much as €300 million if certain milestones are hit. 

Original Article: Bayer, Evotec ink research pact for kidney disease

NEXT ARTICLE

More From BioPortfolio on "Bayer, Evotec ink research pact for kidney disease"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...